The association between lipid-lowering drugs and circulating concentration of PCSK9

被引：3
|
作者：
Reiner, Zeljko [1 ]
机构：
[1] Univ Hosp Ctr Zagreb, Dept Internal Med, Zagreb, Croatia
来源：
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY | 2019年 / 26卷 / 09期
关键词：
SUBTILISIN/KEXIN TYPE 9; CARDIOVASCULAR EVENTS; PREVENTION;
D O I：
10.1177/2047487319840179
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：928 / 929
页数：2
相关论文
共 50 条
  • [21] Management of lipid-lowering therapy in PCSK9 inhibitors-treated patients
    Aretio, Ana
    Campos-Baeta, Ylenia
    Feliu, Anna
    Masip, Montserrat
    Mangues, Ma Antonia
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2018, 40 (01) : 247 - 248
  • [22] LDL-cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid-lowering therapy
    Hamasaki, Masato
    Sakane, Naoki
    Hara, Kazuo
    Kotani, Kazuhiko
    [J]. JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2021, 35 (11)
  • [23] Is there an association between lipid-lowering drugs and cholecystectomy?
    Mamdani, MM
    van Walraven, C
    Bica, A
    Williams, JI
    Naylor, CD
    [J]. AMERICAN JOURNAL OF MEDICINE, 2000, 108 (05): : 418 - 421
  • [24] Lipid-Lowering Drugs and Circulating Adiponectin
    Wanders, Desiree
    Plaisance, Eric P.
    Judd, Robert L.
    [J]. ADIPONECTIN, 2012, 90 : 341 - 374
  • [25] Lower is better: ezetimibe and PCSK9 inhibition join the mainstream of lipid-lowering therapy
    Wojcik, Cezary
    [J]. REVIEWS IN HEALTH CARE, 2016, 7 (01) : 17 - 25
  • [26] Lipid-lowering PCSK9 sequence variants protect against coronary heart disease
    [J]. Nature Clinical Practice Cardiovascular Medicine, 2006, 3 (7): : 350 - 350
  • [27] Drug-Drug Interaction between Antiplatelet Therapy and Lipid-Lowering Agents (Statins and PCSK9 Inhibitors)
    Schroer, Karsten
    Verheugt, Freek W. A.
    Trenk, Dietmar
    [J]. THROMBOSIS AND HAEMOSTASIS, 2023, 123 (02) : 166 - 176
  • [28] PCSK9: a new target for lipid lowering treatment
    Costet, Philippe
    Cariou, Bertrand
    Krempf, Michel
    [J]. SANG THROMBOSE VAISSEAUX, 2007, 19 (03): : 137 - 142
  • [29] Lipid-Lowering Agents: Targets Beyond PCSK9 (vol 124, pg 386, 2019)
    Hegele
    [J]. CIRCULATION RESEARCH, 2020, 127 (10) : E251 - E251
  • [30] LIPID-LOWERING THERAPY WITH PCSK9 INHIBITORS: FAMILIAL HYPERCHOLESTEROLEMIA VS GENERAL POPULATION OUTCOMES
    Matteucci, A.
    Alonzo, A.
    Castello, L.
    Spinelli, A.
    Marino, G.
    Schiaffini, G.
    Di Fusco, S.
    Aquilani, S.
    Aiello, A.
    Colivicchi, F.
    [J]. EUROPEAN HEART JOURNAL SUPPLEMENTS, 2024, 26
12345